




Patent Application
Attorney Docket No.25374A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 11th day of December 2003.

By


(Signature of person mailing)
Tracy Myroft

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Kaoru Shimada et al :

APPLICATION NO.: 10/652,752

: Examiner: To be Assigned

FILING DATE: 8/28/03

: Group Art Unit: To be Assigned

TITLE: Evaluation Method for Predicting Pharmacokinetics of PM using PM Liver Cells of
Drug Metabolizing Enzyme Cytochrome P450 having a Genetic Polymorphism

Hon. Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Date:

12/11/2003

Respectfully submitted,



Kathleen A. Ranney

Attorney for Applicant(s)

Reg. No. 37,702


Pfizer Inc.

Patent Department, MS 8260-1611

Eastern Point Road

Groton, Connecticut 06340

(860) 715-1139



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)								ATTY. DOCKET NO. PC25374				SERIAL NO. 10/652,752							
								APPLICANT Kaoru Shimada et al.											
								FILING DATE 8/28/03				GROUP To be assigned							
U.S. PATENT DOCUMENTS																			
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE						
FOREIGN PATENT DOCUMENTS																			
DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION							
												YES	NO						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																			
		J. Chladek et al., European Journal of Clinical Pharmacology, December 2000, Vol. 56, pp 651-657, "In-vivo indices of CYP2D6 activity: comparison of dextromethorphan metabolic ratios in 4-h urine and 3-h plasma".																	
		A. Guillouzo et al., Chemico-Biological Interactions, 1999, Vol. 121, pp 7-16, "Survival and function of isolated hepatocytes after cryopreservation".																	
		A.P. Li et al., Chemico-Biological Interactions, 1999, Vol. 121, pp 17-35, "Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential".																	
		A.P. Li et al., Chemico-Biological Interactions, 1999, Vol. 121, pp 117-123, "Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: consensus of an international external panel".																	
		K. Kobayashi et al., The Journal of Pharmacology and Experimental Therapeutics, 1997, Vol. 280, pp 927-933, "Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsome".																	
		T. Iwatsubo et al., The Journal of Pharmacology and Experimental Therapeutics, 1997, Vol. 282, pp 909-919, "Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes".																	
		K. Inoue et al., Pharmacogenetics, 1997, Vol. 7, pp 103-113, "Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations".																	
		Z.Q. Liu et al., Acta Pharmacol. Sin., 2001, Vol. 22, No. 1, pp 85-90, Effects of CYP2C19 genotype and CYP2C9 on fluoxetine N-demethylation in human liver microsomes".																	
EXAMINER								DATE CONSIDERED											
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.																			